Phase I study of 2-hydroxyoleic acid (2OHOA) in pediatric patients with malignant glioma and other advanced solid tumors

Trial Profile

Phase I study of 2-hydroxyoleic acid (2OHOA) in pediatric patients with malignant glioma and other advanced solid tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

At a glance

  • Drugs 2-hydroxyoleic acid (Primary)
  • Indications Glioma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 May 2018 According to the Lipopharma media release, U.S. Food and Drug Administration has approved an Investigational New Drug application for this trial.
    • 29 May 2018 According to the Lipopharma media release, this trial will be conducted in collaboration with two leading US paediatric clinical research institutions; Hackensack University Medical Center, in New Jersey and Dana-Farber Cancer Institute in Boston.
    • 13 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top